Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders

Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Miriam Olivola [verfasserIn] Vincenzo Arienti [verfasserIn] Nicola Bassetti [verfasserIn] Serena Civardi [verfasserIn] Natascia Brondino [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	autism spectrum disorders depression esketamine treatment-resistant

Übergeordnetes Werk:	In: EXCLI Journal : Experimental and Clinical Sciences - IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2016, 21(2022), Seite 540-543
Übergeordnetes Werk:	volume:21 ; year:2022 ; pages:540-543

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.17179/excli2022-4694

Katalog-ID:	DOAJ089564669

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ089564669
003	DE-627
005	20230505015108.0
007	cr uuu---uuuuu
008	230505s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.17179/excli2022-4694 \|2 doi
035			\|a (DE-627)DOAJ089564669
035			\|a (DE-599)DOAJ4171bbdbf44e4a408190455e3c98dcad
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
050		0	\|a QH301-705.5
100	0		\|a Miriam Olivola \|e verfasserin \|4 aut
245	1	0	\|a Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine.
650		4	\|a autism spectrum disorders
650		4	\|a depression
650		4	\|a esketamine
650		4	\|a treatment-resistant
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
653		0	\|a Biology (General)
700	0		\|a Vincenzo Arienti \|e verfasserin \|4 aut
700	0		\|a Nicola Bassetti \|e verfasserin \|4 aut
700	0		\|a Serena Civardi \|e verfasserin \|4 aut
700	0		\|a Natascia Brondino \|e verfasserin \|4 aut
773	0	8	\|i In \|t EXCLI Journal : Experimental and Clinical Sciences \|d IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2016 \|g 21(2022), Seite 540-543 \|w (DE-627)377753955 \|w (DE-600)2132560-1 \|x 16112156 \|7 nnns
773	1	8	\|g volume:21 \|g year:2022 \|g pages:540-543
856	4	0	\|u https://doi.org/10.17179/excli2022-4694 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/4171bbdbf44e4a408190455e3c98dcad \|z kostenfrei
856	4	0	\|u https://www.excli.de/index.php/excli/article/view/4694 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1611-2156 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_267
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 21 \|j 2022 \|h 540-543

Indexfelder

author_variant	m o mo v a va n b nb s c sc n b nb
matchkey_str	article:16112156:2022----::soitaaaektmniailihramnrssatersinn
hierarchy_sort_str	2022
callnumber-subject-code	RC
publishDate	2022
allfields	10.17179/excli2022-4694 doi (DE-627)DOAJ089564669 (DE-599)DOAJ4171bbdbf44e4a408190455e3c98dcad DE-627 ger DE-627 rakwb eng RC254-282 QH301-705.5 Miriam Olivola verfasserin aut Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine. autism spectrum disorders depression esketamine treatment-resistant Neoplasms. Tumors. Oncology. Including cancer and carcinogens Biology (General) Vincenzo Arienti verfasserin aut Nicola Bassetti verfasserin aut Serena Civardi verfasserin aut Natascia Brondino verfasserin aut In EXCLI Journal : Experimental and Clinical Sciences IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2016 21(2022), Seite 540-543 (DE-627)377753955 (DE-600)2132560-1 16112156 nnns volume:21 year:2022 pages:540-543 https://doi.org/10.17179/excli2022-4694 kostenfrei https://doaj.org/article/4171bbdbf44e4a408190455e3c98dcad kostenfrei https://www.excli.de/index.php/excli/article/view/4694 kostenfrei https://doaj.org/toc/1611-2156 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2022 540-543
spelling	10.17179/excli2022-4694 doi (DE-627)DOAJ089564669 (DE-599)DOAJ4171bbdbf44e4a408190455e3c98dcad DE-627 ger DE-627 rakwb eng RC254-282 QH301-705.5 Miriam Olivola verfasserin aut Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine. autism spectrum disorders depression esketamine treatment-resistant Neoplasms. Tumors. Oncology. Including cancer and carcinogens Biology (General) Vincenzo Arienti verfasserin aut Nicola Bassetti verfasserin aut Serena Civardi verfasserin aut Natascia Brondino verfasserin aut In EXCLI Journal : Experimental and Clinical Sciences IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2016 21(2022), Seite 540-543 (DE-627)377753955 (DE-600)2132560-1 16112156 nnns volume:21 year:2022 pages:540-543 https://doi.org/10.17179/excli2022-4694 kostenfrei https://doaj.org/article/4171bbdbf44e4a408190455e3c98dcad kostenfrei https://www.excli.de/index.php/excli/article/view/4694 kostenfrei https://doaj.org/toc/1611-2156 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2022 540-543
allfields_unstemmed	10.17179/excli2022-4694 doi (DE-627)DOAJ089564669 (DE-599)DOAJ4171bbdbf44e4a408190455e3c98dcad DE-627 ger DE-627 rakwb eng RC254-282 QH301-705.5 Miriam Olivola verfasserin aut Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine. autism spectrum disorders depression esketamine treatment-resistant Neoplasms. Tumors. Oncology. Including cancer and carcinogens Biology (General) Vincenzo Arienti verfasserin aut Nicola Bassetti verfasserin aut Serena Civardi verfasserin aut Natascia Brondino verfasserin aut In EXCLI Journal : Experimental and Clinical Sciences IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2016 21(2022), Seite 540-543 (DE-627)377753955 (DE-600)2132560-1 16112156 nnns volume:21 year:2022 pages:540-543 https://doi.org/10.17179/excli2022-4694 kostenfrei https://doaj.org/article/4171bbdbf44e4a408190455e3c98dcad kostenfrei https://www.excli.de/index.php/excli/article/view/4694 kostenfrei https://doaj.org/toc/1611-2156 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2022 540-543
allfieldsGer	10.17179/excli2022-4694 doi (DE-627)DOAJ089564669 (DE-599)DOAJ4171bbdbf44e4a408190455e3c98dcad DE-627 ger DE-627 rakwb eng RC254-282 QH301-705.5 Miriam Olivola verfasserin aut Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine. autism spectrum disorders depression esketamine treatment-resistant Neoplasms. Tumors. Oncology. Including cancer and carcinogens Biology (General) Vincenzo Arienti verfasserin aut Nicola Bassetti verfasserin aut Serena Civardi verfasserin aut Natascia Brondino verfasserin aut In EXCLI Journal : Experimental and Clinical Sciences IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2016 21(2022), Seite 540-543 (DE-627)377753955 (DE-600)2132560-1 16112156 nnns volume:21 year:2022 pages:540-543 https://doi.org/10.17179/excli2022-4694 kostenfrei https://doaj.org/article/4171bbdbf44e4a408190455e3c98dcad kostenfrei https://www.excli.de/index.php/excli/article/view/4694 kostenfrei https://doaj.org/toc/1611-2156 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2022 540-543
allfieldsSound	10.17179/excli2022-4694 doi (DE-627)DOAJ089564669 (DE-599)DOAJ4171bbdbf44e4a408190455e3c98dcad DE-627 ger DE-627 rakwb eng RC254-282 QH301-705.5 Miriam Olivola verfasserin aut Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine. autism spectrum disorders depression esketamine treatment-resistant Neoplasms. Tumors. Oncology. Including cancer and carcinogens Biology (General) Vincenzo Arienti verfasserin aut Nicola Bassetti verfasserin aut Serena Civardi verfasserin aut Natascia Brondino verfasserin aut In EXCLI Journal : Experimental and Clinical Sciences IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2016 21(2022), Seite 540-543 (DE-627)377753955 (DE-600)2132560-1 16112156 nnns volume:21 year:2022 pages:540-543 https://doi.org/10.17179/excli2022-4694 kostenfrei https://doaj.org/article/4171bbdbf44e4a408190455e3c98dcad kostenfrei https://www.excli.de/index.php/excli/article/view/4694 kostenfrei https://doaj.org/toc/1611-2156 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 21 2022 540-543
language	English
source	In EXCLI Journal : Experimental and Clinical Sciences 21(2022), Seite 540-543 volume:21 year:2022 pages:540-543
sourceStr	In EXCLI Journal : Experimental and Clinical Sciences 21(2022), Seite 540-543 volume:21 year:2022 pages:540-543
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	autism spectrum disorders depression esketamine treatment-resistant Neoplasms. Tumors. Oncology. Including cancer and carcinogens Biology (General)
isfreeaccess_bool	true
container_title	EXCLI Journal : Experimental and Clinical Sciences
authorswithroles_txt_mv	Miriam Olivola @@aut@@ Vincenzo Arienti @@aut@@ Nicola Bassetti @@aut@@ Serena Civardi @@aut@@ Natascia Brondino @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	377753955
id	DOAJ089564669
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ089564669</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505015108.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17179/excli2022-4694</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ089564669</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4171bbdbf44e4a408190455e3c98dcad</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Miriam Olivola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autism spectrum disorders</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">depression</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">esketamine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">treatment-resistant</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vincenzo Arienti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Bassetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Serena Civardi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natascia Brondino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">EXCLI Journal : Experimental and Clinical Sciences</subfield><subfield code="d">IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2016</subfield><subfield code="g">21(2022), Seite 540-543</subfield><subfield code="w">(DE-627)377753955</subfield><subfield code="w">(DE-600)2132560-1</subfield><subfield code="x">16112156</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:540-543</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17179/excli2022-4694</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4171bbdbf44e4a408190455e3c98dcad</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.excli.de/index.php/excli/article/view/4694</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1611-2156</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2022</subfield><subfield code="h">540-543</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Miriam Olivola
spellingShingle	Miriam Olivola misc RC254-282 misc QH301-705.5 misc autism spectrum disorders misc depression misc esketamine misc treatment-resistant misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens misc Biology (General) Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
authorStr	Miriam Olivola
ppnlink_with_tag_str_mv	@@773@@(DE-627)377753955
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	16112156
topic_title	RC254-282 QH301-705.5 Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders autism spectrum disorders depression esketamine treatment-resistant
topic	misc RC254-282 misc QH301-705.5 misc autism spectrum disorders misc depression misc esketamine misc treatment-resistant misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens misc Biology (General)
topic_unstemmed	misc RC254-282 misc QH301-705.5 misc autism spectrum disorders misc depression misc esketamine misc treatment-resistant misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens misc Biology (General)
topic_browse	misc RC254-282 misc QH301-705.5 misc autism spectrum disorders misc depression misc esketamine misc treatment-resistant misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens misc Biology (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	EXCLI Journal : Experimental and Clinical Sciences
hierarchy_parent_id	377753955
hierarchy_top_title	EXCLI Journal : Experimental and Clinical Sciences
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)377753955 (DE-600)2132560-1
title	Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
ctrlnum	(DE-627)DOAJ089564669 (DE-599)DOAJ4171bbdbf44e4a408190455e3c98dcad
title_full	Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
author_sort	Miriam Olivola
journal	EXCLI Journal : Experimental and Clinical Sciences
journalStr	EXCLI Journal : Experimental and Clinical Sciences
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	540
author_browse	Miriam Olivola Vincenzo Arienti Nicola Bassetti Serena Civardi Natascia Brondino
container_volume	21
class	RC254-282 QH301-705.5
format_se	Elektronische Aufsätze
author-letter	Miriam Olivola
doi_str_mv	10.17179/excli2022-4694
author2-role	verfasserin
title_sort	use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
callnumber	RC254-282
title_auth	Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
abstract	Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine.
abstractGer	Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine.
abstract_unstemmed	Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
url	https://doi.org/10.17179/excli2022-4694 https://doaj.org/article/4171bbdbf44e4a408190455e3c98dcad https://www.excli.de/index.php/excli/article/view/4694 https://doaj.org/toc/1611-2156
remote_bool	true
author2	Vincenzo Arienti Nicola Bassetti Serena Civardi Natascia Brondino
author2Str	Vincenzo Arienti Nicola Bassetti Serena Civardi Natascia Brondino
ppnlink	377753955
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.17179/excli2022-4694
callnumber-a	RC254-282
up_date	2024-07-03T23:42:00.582Z
_version_	1803603275243585536
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ089564669</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505015108.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230505s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17179/excli2022-4694</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ089564669</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4171bbdbf44e4a408190455e3c98dcad</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH301-705.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Miriam Olivola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently approved as an add-on medication for treatment-resistant depression (TRD), but it has never been used in ASD with comorbid major depression. Of note, a pilot study of intranasal ketamine has shown no effect on social withdrawal in ASD without depression. The present case report describes the first girl with ASD and comorbid TRD treated with intranasal esketamine.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">autism spectrum disorders</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">depression</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">esketamine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">treatment-resistant</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Biology (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vincenzo Arienti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Bassetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Serena Civardi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Natascia Brondino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">EXCLI Journal : Experimental and Clinical Sciences</subfield><subfield code="d">IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2016</subfield><subfield code="g">21(2022), Seite 540-543</subfield><subfield code="w">(DE-627)377753955</subfield><subfield code="w">(DE-600)2132560-1</subfield><subfield code="x">16112156</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:21</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:540-543</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17179/excli2022-4694</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4171bbdbf44e4a408190455e3c98dcad</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.excli.de/index.php/excli/article/view/4694</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1611-2156</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">21</subfield><subfield code="j">2022</subfield><subfield code="h">540-543</subfield></datafield></record></collection>
score	7.4023256

Nicht das Richtige dabei?

Schreiben Sie uns!

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?